Buena Vista Images/DigitalVision via Getty Images
Summary
- Novo Nordisk stock remains a great buy at every dips, thanks to its expanding 2030 TAM to $150B, highly profitable growth trend, and improving balance sheet.
- Readers must also note that its growing oral/injectable diabetes/obesity pipelines, with its late stage candidates being highly promising.
- Combined with the excellent patient adherence rate and raised guidance/estimates, we believe that consumers’ vote of confidence may bring about NVO’s sustained top/bottom line growth and shareholder returns.
We previous covered Novo Nordisk (NVO) stock in October 2023, discussing how its obesity/diabetes drug, Wegovy/Ozempic, are projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030.
Despite its inflated P/E valuations over the pharmaceutical median, we had rated the stock as a Buy then, attributed to its highly profitable growth trend and potential applications for new indications.
READ FULL ARTICLE HERE!
